#1
REVIEW
Feigao Li, Wenyan Cui, Guangliang Huang, Yunfei Tian, Xinhui Zhang, Wenjuan He, Qian Sun, Xiaojuan Zhao, Yonghong Zhao, Dan Li, Xizhe Liu, Xiuju Liu
To compare the clinical effectiveness and safety of novel biologics for the treatment of lupus nephritis based on a reticulated meta-analysis approach. Registered clinical trials in 4 major databases (PubMed, Embase, Web of Science, The Cochrane Register of Clinical Trials) and ClinicalTrials.gov were systematically searched with a search time frame of build to June 2022. And we screened registered randomized controlled clinical trials of biologics for the treatment of lupus nephritis according to the protocol's nadir criteria...
July 18, 2023: Clinical and Experimental Medicine
#2
RANDOMIZED CONTROLLED TRIAL
P Robinson, Michael S Schechter, Peter D Sly, Kaye Winfield, Julie Smith, Siobhain Brennan, Masaharu Shinkai, Markus O Henke, Bruce K Rubin
The clinically significant actions of oral azithromycin in modifying progressive cystic fibrosis (CF) lung disease have been well documented. In vitro and clinical data suggests that clarithromycin has immunomodulatory properties similar to other 14-member macrolides, however two previously reported short term, open label trials of clairthromycin in small numbers of patients with CF failed to show significant benefits in modifying lung function or inflammation. We performed an international double blind, cross-over trial in which 63 subjects with CF were studied while receiving either placeo or 500 mg oral clarithromycin twice daily for 5 months, with a 1-month wash-out...
June 2012: Pediatric Pulmonology
#3
RANDOMIZED CONTROLLED TRIAL
M Loos, V W Rahlfs
Design and evaluation of the controlled clinical trial are thoroughly discussed by giving an example for testing a sodium pentosan polysulphate/nicotinic acid combination (Compuron). 60 patients with cerebral vascular disorders were randomly allocated to the two treatments and received medication over a period of eight weeks. A detailed biostatistical analysis of the data led to the following conclusions: 1. Regarding the target symptoms headache, nausea, sleep disturbance, reduced alertness, reduced ability for contacts and moods significant differences in favor of the active medication beginning with the sixth treatment week...
April 1976: Arzneimittel-Forschung
1